Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, ORIC Pharmaceuticals Inc’s stock clocked out at $1.19M, up 1571148% from its previous closing price of $9.22. In other words, the price has increased by $1571148 from its previous closing price. On the day, 1.57 million shares were traded. ORIC stock price reached its highest trading level at $9.5 during the session, while it also had its lowest trading level at $8.99.
Ratios:
To gain a deeper understanding of ORIC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.00 and its Current Ratio is at 12.00. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on October 31, 2024, initiated with a Overweight rating and assigned the stock a target price of $20.
On September 06, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 12 ’25 when Piscitelli Dominic sold 300 shares for $10.00 per share. The transaction valued at 3,000 led to the insider holds 101,817 shares of the business.
Piscitelli Dominic sold 2,976 shares of ORIC for $29,777 on Jun 11 ’25. The Chief Financial Officer now owns 102,117 shares after completing the transaction at $10.01 per share. On Jun 10 ’25, another insider, Piscitelli Dominic, who serves as the Chief Financial Officer of the company, sold 324 shares for $10.00 each. As a result, the insider received 3,240 and left with 105,093 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORIC now has a Market Capitalization of 793383360 and an Enterprise Value of 466823040.
Stock Price History:
The Beta on a monthly basis for ORIC is 1.48, which has changed by 0.30209792 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, ORIC has reached a high of $14.67, while it has fallen to a 52-week low of $3.90. The 50-Day Moving Average of the stock is 43.57%, while the 200-Day Moving Average is calculated to be 11.52%.
Shares Statistics:
It appears that ORIC traded 1.19M shares on average per day over the past three months and 1007270 shares per day over the past ten days. A total of 71.08M shares are outstanding, with a floating share count of 47.89M. Insiders hold about 43.81% of the company’s shares, while institutions hold 69.91% stake in the company. Shares short for ORIC as of 1748563200 were 13348681 with a Short Ratio of 11.17, compared to 1745971200 on 11192498. Therefore, it implies a Short% of Shares Outstanding of 13348681 and a Short% of Float of 19.11.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of ORIC Pharmaceuticals Inc (ORIC) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.29 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.27 and -$1.98 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.75, with 10.0 analysts recommending between -$1.24 and -$2.15.
